<SEC-DOCUMENT>0001558370-21-004976.txt : 20210428
<SEC-HEADER>0001558370-21-004976.hdr.sgml : 20210428
<ACCEPTANCE-DATETIME>20210428060437
ACCESSION NUMBER:		0001558370-21-004976
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		15
CONFORMED PERIOD OF REPORT:	20210428
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20210428
DATE AS OF CHANGE:		20210428

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Protalix BioTherapeutics, Inc.
		CENTRAL INDEX KEY:			0001006281
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				650643773
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-33357
		FILM NUMBER:		21861178

	BUSINESS ADDRESS:	
		STREET 1:		2 UNIVERSITY PLAZA
		STREET 2:		SUITE 100
		CITY:			HACKENSACK
		STATE:			NJ
		ZIP:			07601
		BUSINESS PHONE:		201-696-9345

	MAIL ADDRESS:	
		STREET 1:		2 UNIVERSITY PLAZA
		STREET 2:		SUITE 100
		CITY:			HACKENSACK
		STATE:			NJ
		ZIP:			07601

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ORTHODONTIX INC
		DATE OF NAME CHANGE:	19980422

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	EMBASSY ACQUISITION CORP
		DATE OF NAME CHANGE:	19960124
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>plx-20210428x8k.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='UTF-8'?>

      <!-- iXBRL document created with: Toppan Merrill Bridge iXBRL 9.6.7713.40453 -->
      <!-- Based on: iXBRL 1.1 -->
      <!-- Created on: 4/28/2021 10:04:21 AM -->
      <!-- iXBRL Library version: 1.0.7713.40461 -->
      <!-- iXBRL Service Job ID: 3cea9e43-7246-4fa0-acfa-96f06f0a42c6 -->

  <html xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31" xmlns="http://www.w3.org/1999/xhtml" xmlns:plx="http://protalix.com/20210428" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrli="http://www.xbrl.org/2003/instance"><head><meta http-equiv="content-type" content="text/html" /><title></title></head><body><div style="margin-top:30pt;"></div><div style="display:none;"><ix:header><ix:hidden><ix:nonNumeric contextRef="Duration_4_28_2021_To_4_28_2021_mMZ_Yz-jLEqRey88TjsIbg" name="dei:EntityCentralIndexKey" id="Tc_NEjgYrOXekCRXK79Omb3mQ_2_1">0001006281</ix:nonNumeric><ix:nonNumeric contextRef="Duration_4_28_2021_To_4_28_2021_mMZ_Yz-jLEqRey88TjsIbg" name="dei:AmendmentFlag" id="Tc_uiILK5vIgk-ofKrWo2bExg_3_1">false</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:href="plx-20210428.xsd" xlink:type="simple"></link:schemaRef></ix:references><ix:resources><xbrli:context id="Duration_4_28_2021_To_4_28_2021_mMZ_Yz-jLEqRey88TjsIbg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-28</xbrli:startDate><xbrli:endDate>2021-04-28</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;min-height:13.8pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1pt;padding-bottom:1pt;padding-top:1pt;text-align:center;border-bottom:1.0pt solid #000000;border-top:3.0pt solid #000000;margin:0pt;"><span style="font-size:1pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:3pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_66e6d4a8_9435_4cc8_9e61_2e7ee2b3d21b"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">UNITED STATES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 4pt 0pt;"><b style="font-weight:bold;">Washington, D.C. 20549</b></p><div style="font-family:'Times New Roman','Times','serif';font-size:12.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">FORM&#160;</b><ix:nonNumeric contextRef="Duration_4_28_2021_To_4_28_2021_mMZ_Yz-jLEqRey88TjsIbg" name="dei:DocumentType" id="Narr_PUbWSG3oeEeFcMp7FmPd2w"><b style="font-weight:bold;">8-K</b></ix:nonNumeric></p><div style="font-family:'Times New Roman','Times','serif';font-size:12.0pt;margin-bottom:4pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">CURRENT REPORT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Pursuant to Section&#160;13 or 15(d)&#160;of</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">the Securities Exchange Act of 1934</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 4pt 0pt;"><b style="font-weight:bold;">Date of Report (Date of Earliest Event Reported): </b><ix:nonNumeric contextRef="Duration_4_28_2021_To_4_28_2021_mMZ_Yz-jLEqRey88TjsIbg" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate" id="Narr_eaYniF-Rxk22yS_YV5CdGA"><b style="font-weight:bold;">April&#160;28, 2021</b></ix:nonNumeric></p><div style="font-family:'Times New Roman','Times','serif';font-size:12.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:14pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_4_28_2021_To_4_28_2021_mMZ_Yz-jLEqRey88TjsIbg" name="dei:EntityRegistrantName" id="Narr_djafTGn2yUGPnkdzzIK-kA"><b style="font-weight:bold;">Protalix BioTherapeutics,&#160;Inc.</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Exact name of registrant as specified in its charter)</b></p><div style="font-family:'Times New Roman','Times','serif';font-size:12.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_db44e2d3_a4d8_4690_a9da_b28605fc200d"></a><a id="Tc_2fd-kuO26kuswfmE35ARMw_2_0"></a><a id="Tc_7AWgo4C_GEqP473gXRtmFg_2_2"></a><a id="Tc_mHWy862Af06YhL31XSnPaw_2_4"></a><a id="Tc_Ypr8MJQNK0Kyf0C433ynVg_6_0"></a><a id="Tc_IV7UM3HhK0mKAjxDCNQoTw_7_0"></a><a id="Tc_Ey9p6PTAI0iL_EIX1R6Z3w_7_4"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:34.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:25.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:34.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:34.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_4_28_2021_To_4_28_2021_mMZ_Yz-jLEqRey88TjsIbg" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="Tc_nJVheu79-UGOwoLOKqNN5A_1_0"><b style="font-weight:bold;">Delaware</b></ix:nonNumeric></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:25.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_4_28_2021_To_4_28_2021_mMZ_Yz-jLEqRey88TjsIbg" name="dei:EntityFileNumber" id="Tc_9mhPitmW-EKbtgzwPvBBUA_1_2"><b style="font-weight:bold;">001-33357</b></ix:nonNumeric></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:34.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_4_28_2021_To_4_28_2021_mMZ_Yz-jLEqRey88TjsIbg" name="dei:EntityTaxIdentificationNumber" id="Tc_nS034P5c90urU08TDBU63Q_1_4"><b style="font-weight:bold;">65-0643773</b></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:bottom;width:34.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(State or other jurisdiction</b><br /><b style="font-weight:bold;">of incorporation)</b></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:25.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Commission File Number)</b></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:34.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(IRS Employer<br />Identification No.)</b></p></td></tr><tr><td style="vertical-align:bottom;width:34.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:25.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:34.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:34.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_4_28_2021_To_4_28_2021_mMZ_Yz-jLEqRey88TjsIbg" name="dei:EntityAddressAddressLine1" id="Tc_t3SGCGIj10S-ACspcGI7Rg_4_0"><b style="font-weight:bold;">2 University Plaza</b></ix:nonNumeric></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:25.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:34.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:34.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_4_28_2021_To_4_28_2021_mMZ_Yz-jLEqRey88TjsIbg" name="dei:EntityAddressAddressLine2" id="Tc_yLhS9j6LfUmb5vHwN7-vPg_5_0"><b style="font-weight:bold;">Suite 100</b></ix:nonNumeric></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:25.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:34.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:34.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_4_28_2021_To_4_28_2021_mMZ_Yz-jLEqRey88TjsIbg" name="dei:EntityAddressCityOrTown" id="Narr_RRcw4rXCdE6xQcN-hlkvsg"><b style="font-weight:bold;">Hackensack</b></ix:nonNumeric><b style="font-weight:bold;">, </b><ix:nonNumeric contextRef="Duration_4_28_2021_To_4_28_2021_mMZ_Yz-jLEqRey88TjsIbg" name="dei:EntityAddressStateOrProvince" id="Narr_WByoiqAwnEaIOYlAGJYafw"><b style="font-weight:bold;">NJ</b></ix:nonNumeric></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:25.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:34.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_4_28_2021_To_4_28_2021_mMZ_Yz-jLEqRey88TjsIbg" name="dei:EntityAddressPostalZipCode" id="Tc_sxyB9VDpM0KG5ReXoHKIvw_6_4"><b style="font-weight:bold;">07601</b></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:bottom;width:34.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Address of principal executive offices)</b></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:25.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:34.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Zip Code)</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;">&#160;<b style="font-weight:bold;">Registrant&#8217;s telephone number, including area code </b><ix:nonNumeric contextRef="Duration_4_28_2021_To_4_28_2021_mMZ_Yz-jLEqRey88TjsIbg" name="dei:CityAreaCode" id="Narr_gC2_YoCguEq67usn4aF9SA"><b style="font-weight:bold;">201</b></ix:nonNumeric><b style="font-weight:bold;">-</b><ix:nonNumeric contextRef="Duration_4_28_2021_To_4_28_2021_mMZ_Yz-jLEqRey88TjsIbg" name="dei:LocalPhoneNumber" id="Narr_6HcoqHSqhEi2BvxMzU2XXQ"><b style="font-weight:bold;">696-9345</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Former name or former address, if changed since last report.)</b></p><div style="font-family:'Times New Roman','Times','serif';font-size:12.0pt;margin-bottom:10pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Check the appropriate box below if the Form&#160;8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (<i style="font-style:italic;">see</i> General Instruction A.2. below):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><ix:nonNumeric contextRef="Duration_4_28_2021_To_4_28_2021_mMZ_Yz-jLEqRey88TjsIbg" format="ixt-sec:boolballotbox" name="dei:WrittenCommunications" id="Narr_IRkktNuU8Eux7H9NET-VhQ"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></ix:nonNumeric>&#160;&#160;&#160;&#160;Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><ix:nonNumeric contextRef="Duration_4_28_2021_To_4_28_2021_mMZ_Yz-jLEqRey88TjsIbg" format="ixt-sec:boolballotbox" name="dei:SolicitingMaterial" id="Narr_puWYY9YjhEWb1KFJoKzFgA"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></ix:nonNumeric>&#160;&#160;&#160;&#160;Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><ix:nonNumeric contextRef="Duration_4_28_2021_To_4_28_2021_mMZ_Yz-jLEqRey88TjsIbg" format="ixt-sec:boolballotbox" name="dei:PreCommencementTenderOffer" id="Narr_Z9DEKQG3wkCiSqYFuso-gw"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></ix:nonNumeric>&#160;&#160;&#160;&#160;Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_4_28_2021_To_4_28_2021_mMZ_Yz-jLEqRey88TjsIbg" format="ixt-sec:boolballotbox" name="dei:PreCommencementIssuerTenderOffer" id="Narr_jsVqEkTPZkmq5SdFO5DHkg"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></ix:nonNumeric>&#160;&#160;&#160;&#160;Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Securities registered pursuant to Section&#160;12(b)&#160;of the Act:</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_e77e804a_d223_4729_927d_c6bf13fbe4e3"></a><a id="Tc_4KdCRyAvY0ipi2D4pEHMfw_1_0"></a><a id="Tc_fcCsDkXvmEyWF4Hv_ETGFA_1_1"></a><a id="Tc_cpMAY-TxKUC5DKrEclwLDw_1_2"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:40%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:19.99%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:39.99%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:40%;border-bottom:1.0pt solid #000000;border-left:1.0pt solid #000000;border-right:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt 4.9pt 0pt 4.9pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Title of each class</p></td><td style="vertical-align:bottom;width:19.99%;border-bottom:1.0pt solid #000000;border-right:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt 4.9pt 0pt 4.9pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Trading Symbol(s)</p></td><td style="vertical-align:bottom;width:39.99%;border-bottom:1.0pt solid #000000;border-right:1.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;padding:0pt 4.9pt 0pt 4.9pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Name of each exchange on which registered</p></td></tr><tr><td style="vertical-align:top;width:40%;border-bottom:1.0pt solid #000000;border-left:1.0pt solid #000000;border-right:1.0pt solid #000000;margin:0pt;padding:0pt 4.9pt 0pt 4.9pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_4_28_2021_To_4_28_2021_mMZ_Yz-jLEqRey88TjsIbg" name="dei:Security12bTitle" id="Tc_LPsbvGXSLEGpTDwM8uyYOA_2_0">Common stock, $0.001 par value</ix:nonNumeric></p></td><td style="vertical-align:top;width:19.99%;border-bottom:1.0pt solid #000000;border-right:1.0pt solid #000000;margin:0pt;padding:0pt 4.9pt 0pt 4.9pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_4_28_2021_To_4_28_2021_mMZ_Yz-jLEqRey88TjsIbg" name="dei:TradingSymbol" id="Tc_DHROVgBOTUSFKg2_9Vkmhw_2_1">PLX</ix:nonNumeric></p></td><td style="vertical-align:top;width:39.99%;border-bottom:1.0pt solid #000000;border-right:1.0pt solid #000000;margin:0pt;padding:0pt 4.9pt 0pt 4.9pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_4_28_2021_To_4_28_2021_mMZ_Yz-jLEqRey88TjsIbg" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="Tc_kzu8ATU73kytCHiHZsXtBA_2_2">NYSE American</ix:nonNumeric></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule&#160;405 of the Securities Act of 1933 (17 CFR &#167;230.405) or Rule&#160;12b-2 of the Securities Exchange Act of 1934 (17 CFR &#167;240.12b-2).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 10pt 0pt;">Emerging growth company <ix:nonNumeric contextRef="Duration_4_28_2021_To_4_28_2021_mMZ_Yz-jLEqRey88TjsIbg" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany" id="Narr_I6bNWiXTeUebQXavJonwMA"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a)&#160;of the Exchange Act. <span style="font-family:'Times New Roman';">&#9723;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:3pt;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1pt;padding-bottom:1pt;padding-top:1pt;border-bottom:3.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;"><span style="font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><span style="font-size:0pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Item&#160;8.01&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Other Events</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:11.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:88.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">On April&#160;28, 2021, Protalix BioTherapeutics, Inc., a Delaware corporation (the &#8220;Company&#8221;), issued a press release, together with its development and commercialization partner, Chiesi Global Rare Diseases, a unit of Chiesi Farmaceutici S.p.A., announcing that that they received a Complete Response Letter (CRL) from the U.S.&#160;Food and Drug Administration (FDA) regarding the Biologics License Application (BLA) seeking accelerated approval of pegunigalsidase alfa (PRX-102) for the proposed treatment of adult patients with Fabry disease. A copy of the press release is attached as Exhibit&#160;99.1 to this Current Report on Form 8-K and is incorporated herein by reference.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Item&#160;9.01&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Financial Statements and Exhibits</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">(d)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Exhibits</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">99.1&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<a style="-sec-extract:exhibit;" href="plx-20210428xex99d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:left;">Press release dated April&#160;28, 2021</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">104&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<span style="background-color:#ffffff;">Cover Page Interactive Data File (embedded within the Inline XBRL document)</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">SIGNATURES</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:56.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:3.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:6.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:33.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:56.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date: April&#160;28, 2021</p></td><td colspan="3" style="vertical-align:top;width:43.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:56.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:3.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:6.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:33.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:56.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:3.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td colspan="2" style="vertical-align:top;width:40.02%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Dror Bashan</p></td></tr><tr><td style="vertical-align:top;width:56.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:3.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:6.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name:</p></td><td style="vertical-align:top;width:33.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Dror Bashan</p></td></tr><tr><td style="vertical-align:top;width:56.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:3.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:6.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title:</p></td><td style="vertical-align:top;width:33.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">President and Chief Executive Officer</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:avoid;width:79.3%;border:0;"></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>plx-20210428xex99d1.htm
<DESCRIPTION>EX-99.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.10.0.88--><!--Created on: 4/28/2021 10:04:15 AM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;min-height:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:right;margin:0pt;"><b style="font-weight:bold;">Exhibit 99.1</b></p></div><div style="clear:both;max-width:100%;position:relative;"><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;width:99.89%;"><tr style="height:1pt;"><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><img src="plx-20210428xex99d1001.jpg" alt="Graphic" style="display:inline-block;height:39pt;left:0%;padding-bottom:0pt;position:relative;top:0pt;width:128.25pt;"></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:right;margin:0pt;"><img src="plx-20210428xex99d1002.jpg" alt="Graphic" style="display:inline-block;height:47.25pt;left:0%;padding-bottom:0.75pt;position:relative;top:0pt;width:132pt;"></p></td></tr></table></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.28;margin:0pt 0pt 8pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;text-align:center;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:14pt;font-weight:bold;">Protalix BioTherapeutics and Chiesi Global Rare Diseases Receive<br>Complete Response Letter for Pegunigalsidase Alfa from FDA</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">CARMIEL, Israel and BOSTON, Mass. &#8211; </b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">April&#160;28, 2021 &#8211; Protalix BioTherapeutics, Inc. (NYSE American:PLX) (TASE:PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx</font><sup style="font-family:'Times New Roman','Times','serif';font-size:9pt;vertical-align:top;">&#174;</sup><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;"> plant cell-based protein expression system, and Chiesi Global Rare Diseases, a business unit of Chiesi Farmaceutici S.p.A., an international research-focused healthcare Group (Chiesi Group), today announced that they received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding the Biologics License Application (BLA) seeking accelerated approval of pegunigalsidase alfa (PRX-102) for the proposed treatment of adult patients with Fabry disease.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Protalix and Chiesi are studying the CRL to assess the most expedient regulatory approach to reach an understanding with the FDA on additional actions required to obtain approval of PRX-102, and will provide an update soon.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8220;While disappointing, we remain confident in the strength of our data and in the depth of our program,&#8221; said Dror Bashan, Protalix&#8217;s President and Chief Executive Officer. &#8220;We remain committed to the program and to working with the FDA and Chiesi toward the approval of PRX-102.&#8221;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8220;Based on extensive clinical data including results from the Phase&#160;III BRIDGE clinical trial of PRX-102 for the proposed treatment of Fabry disease, we continue to feel strongly that PRX-102 is an important option for the treatment of Fabry disease in adult patients, and we are continuing with our efforts to make this therapy available to patients,&#8221; said Giacomo Chiesi, Head of Chiesi Global Rare Diseases. &#8220;We thank the patients and clinicians participating in our completed and ongoing clinical studies evaluating PRX-102. We are continuing to coordinate closely with the FDA to address and quickly resolve the deficiencies contained in the CRL.&#8221;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Fabry disease is an X-linked inherited disease caused by deficient activity of the lysosomal &#945;-Galactosidase-A enzyme, resulting in progressive accumulation of abnormal deposits of a fatty substance called globotriaosylceramide (Gb</font><sub style="font-family:'Times New Roman','Times','serif';font-size:9pt;vertical-align:sub;">3</sub><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">) in the blood and blood vessel walls throughout the human body. Symptoms of Gb</font><sub style="font-family:'Times New Roman','Times','serif';font-size:9pt;vertical-align:sub;">3</sub><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;"> deposition range from episodes of pain, gastrointestinal (GI) symptoms, fatigue, angiokeratoma, and abnormal sweating to serious complications including cardiovascular, renal, and cerebrovascular events.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">The PRX-102 BLA was initially submitted under the accelerated approval pathway and was granted Priority Review by the FDA. Priority Review is granted to therapies that the FDA determines have the potential to provide significant improvements in the treatment, diagnosis or prevention of serious conditions. The BLA submission for PRX-102 included a comprehensive set of preclinical, clinical, and manufacturing data compiled from the completed Phase&#160;I/II </font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-indent:0pt;margin:0pt 0pt 12pt 18pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">clinical trial of PRX-102, including the related extension study succeeding the Phase&#160;I/II clinical trial, interim clinical data from the Phase III BRIDGE switch-over study and safety data from Protalix&#8217;s on-going clinical studies of PRX-102 in patients receiving 1&#160;mg/kg every other week.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">We remain committed to the Phase III clinical program which is progressing, and patients continue to receive PRX-102 treatment in the ongoing </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">BALANCE study sponsored by Protalix and various </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">long-term extension studies</font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">. In addition, </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Chiesi provides access to pegunigalsidase alfa through its Expanded Access Program (EAP) for Fabry disease patients in the United States who cannot be adequately treated with currently available FDA-approved drugs. The EAP is open to patients with a clinical diagnosis of Fabry disease who, in the opinion of the treating physician, have no comparable or satisfactory alternative treatment options with currently available FDA-approved therapies for Fabry disease. Other eligibility criteria apply. The Expanded Access Program is listed on ClinicalTrials.gov Identifier: NCT04552691 (</font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">https://clinicaltrials.gov/ct2/show/NCT04552691</font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">). Additional information on Chiesi&#8217;s Expanded Access policy is available at </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">https://www.chiesiusa.com/sustainability/expanded-access-programs/</font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">. Treating physicians must submit requests on behalf of their patients for consideration via the EAP request portal at </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">https://chiesi.versaic.com</font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">. As originally planned, Chiesi will continue to coordinate with the European Medicines Agency (EMA) to file for regulatory approval of PRX-102 in the European Union this year.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">About Pegunigalsidase Alfa (PRX-102) </b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Pegunigalsidase alfa (PRX-102) is an investigational, plant cell culture-expressed, and chemically modified stabilized version of the recombinant &#945;-Galactosidase-A enzyme. Protein sub-units are covalently bound via chemical cross-linking using short PEG moieties, resulting in a molecule with unique pharmacokinetic parameters. In clinical studies, PRX-102 has been observed to have a circulatory half-life of approximately 80 hours. Protalix designed PRX-102 to potentially address the continued unmet clinical need in Fabry patients.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">About Protalix BioTherapeutics, Inc.</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Protalix is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx</font><sup style="font-family:'Times New Roman','Times','serif';font-size:9pt;vertical-align:top;">&#174;</sup><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">. Protalix was the first company to gain FDA approval of a protein produced through plant cell-based in suspension expression system. Protalix&#8217;s unique expression system represents a new method for developing recombinant proteins in an industrial-scale manner.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Protalix&#8217;s first product manufactured by ProCellEx, taliglucerase alfa, was approved by the FDA in May 2012 and, subsequently, by the regulatory authorities of other countries. Protalix has licensed to Pfizer Inc. the worldwide development and commercialization rights for taliglucerase alfa, excluding Brazil, where Protalix retains full rights.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Protalix&#8217;s development pipeline consists of proprietary versions of recombinant therapeutic proteins that target established pharmaceutical markets, including the following product candidates: pegunigalsidase alfa, a modified stabilized version of the recombinant human &#945;--Galactosidase--A protein for the treatment of Fabry disease; alidornase alfa or PRX-110, for the treatment of various human respiratory diseases or conditions; PRX-115, a plant cell-expressed </font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">recombinant PEGylated uricase for the treatment of refractory gout; PRX-119, a plant cell-expressed long action DNase I for the treatment of NETs-related diseases; and others. Protalix has partnered with Chiesi Farmaceutici S.p.A., both in the United States and outside the United States, for the development and commercialization of pegunigalsidase alfa, and with SarcoMed USA, Inc. for the worldwide development and commercialization of PRX-110 for use in the treatment of any human respiratory disease or condition including, but not limited to, sarcoidosis, pulmonary fibrosis, and other related diseases via inhaled delivery.</font></p><p style="font-family:'Times New Roman Bold';font-size:12pt;font-weight:bold;line-height:1.19;text-transform:uppercase;margin:0pt 0pt 12pt 0pt;">About Chiesi Global Rare Diseases</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:14pt 0pt 0pt 0pt;">Chiesi Global Rare Diseases is a business unit of the Chiesi Group established in February 2020 and focused on research and development of treatments for rare and ultra-rare disorders. The Global Rare Diseases unit works in collaboration with Chiesi Group to harness the full resources and capabilities of our global network to bring innovative new treatment options to people living with rare diseases, many of whom have limited or no treatments available. The unit is also a dedicated partner with global leaders in patient advocacy, research and patient care. For more information visit&#160;www.chiesiglobalrarediseases.com<u style="color:#0563c1;text-decoration:underline;text-decoration-color:#0563c1;">.</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:14pt 0pt 12pt 0pt;"><b style="font-weight:bold;">About Chiesi Group</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:14pt 0pt 0pt 0pt;">Based in Parma, Italy, Chiesi Farmaceutici is an international research-focused healthcare group with 85 years of experience in the pharmaceutical industry and a global presence in 29 countries. Chiesi researches, develops, and markets innovative drugs in the respiratory therapeutics, specialist medicine, and rare disease areas. Its R&amp;D organization is headquartered in Parma (Italy), and is integrated with R&amp;D groups in France, the USA, the UK, and Sweden to advance Chiesi&#8217;s pre-clinical, clinical, and registration programs. Chiesi employs nearly 6,000 people.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:14pt 0pt 0pt 0pt;">Chiesi Group is a certified Benefit corporation. For more information, please visit www.chiesi.com<u style="color:#0563c1;text-decoration:underline;text-decoration-color:#0563c1;">.</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:14pt 0pt 12pt 0pt;"><b style="color:#373737;font-weight:bold;">Protalix BioTherapeutics Forward-Looking Statements Disclaimer</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:14pt 0pt 0pt 0pt;">To the extent that statements in this press release are not strictly historical, all such statements are forward-looking, and are made pursuant to the safe-harbor provisions of the Private Securities Litigation Reform Act of 1995. The terms &#8220;expect,&#8221; &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221; &#8220;project,&#8221; &#8220;may,&#8221; &#8220;plan,&#8221; &#8220;will,&#8221; &#8220;would,&#8221; &#8220;should&#8221; and &#8220;intend,&#8221; and other words or phrases of similar import are intended to identify forward-looking statements. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual future experience and results to differ materially from the statements made. These statements are based on our current beliefs and expectations as to such future outcomes. Drug discovery and development involve a high degree of risk and the final results of a clinical trial may be different than the preliminary findings for the clinical trial. Factors that might cause material differences include, among others: Risks related to the timing and progress of the preparation of an updated BLA addressing the complete response letter; Risks related to the timing, progress and likelihood of final approval by the FDA of a resubmitted BLA for PRX-102 and, if approved, whether the use of PRX-102 will be commercially successful; failure or delay in the commencement or completion of our preclinical studies and clinical trials, which may be </p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;padding-bottom:14pt;margin:0pt;">caused by several factors, including: slower than expected rates of patient recruitment; unforeseen safety issues; determination of dosing issues; lack of effectiveness during clinical trials; inability or unwillingness of medical investigators and institutional review boards to follow our clinical protocols; and inability to monitor patients adequately during or after treatment; risks associated with the novel coronavirus disease, or COVID-19, outbreak, which may adversely impact our business, preclinical studies and clinical trials; risks related to any transactions we may effect in the public or private equity markets to raise capital to finance future research and development activities, general and administrative expenses and working capital; the risk that the results of the clinical trials of our product candidates will not support the applicable claims of safety or efficacy, or that our product candidates will not have the desired effects or will be associated with undesirable side effects or other unexpected characteristics; risks related to our ability to maintain and manage our relationship with our collaborators, distributors or partners; risks related to the amount and sufficiency of our cash and cash equivalents; risks relating to our ability to make scheduled payments of the principal of, to pay interest on or to refinance our outstanding notes or any other indebtedness; our dependence on performance by third party providers of services and supplies, including without limitation, clinical trial services; delays in our preparation and filing of applications for regulatory approval; delays in the approval or potential rejection of any applications we file with the FDA, EMA or other health regulatory authorities, and other risks relating to the review process; the inherent risks and uncertainties in developing drug platforms and products of the type we are developing; the impact of development of competing therapies and/or technologies by other companies and institutions; potential product liability risks, and risks of securing adequate levels of product liability and other necessary insurance coverage; and other factors described in our filings with the U.S.&#160;Securities and Exchange Commission. The statements in this press release are valid only as of the date hereof and we disclaim any obligation to update this information, except as may be required by law.</p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><b style="color:#373737;font-weight:bold;">Protalix BioTherapeutics Media Contact</b></p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="color:#333333;letter-spacing:-0.1pt;">Chuck Padala, Managing Director<br>LifeSci Advisors<br>+1-646-627-8390<br></font>chuck@lifesciadvisors.com</p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="color:#373737;font-weight:bold;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</font></p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><b style="color:#373737;font-weight:bold;">Chiesi Global Rare Diseases Media Contact</b></p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="color:#373737;">Jenna Urban</font></p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="color:#373737;">Berry &amp; Company Public Relations</font></p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="color:#373737;">1-212-253-8881</font></p><p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;">jurban@berrypr.com</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:avoid;width:76.47%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>plx-20210428xex99d1001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 plx-20210428xex99d1001.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !. 0$# 2(  A$! Q$!_\0
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M#*#E4ES;(FHHHH.@\1^%OB#3-#^W_P!HW20>81MW=^E>B2_$7PQ&A;^TXC[
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MZE2#7D'A>?\ X0WXC7FB3-LM+D_NL].^*]CK/N]$TZ]NTN[BU1YTQM<CD8H
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)04 2T444 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>plx-20210428xex99d1002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 plx-20210428xex99d1002.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !? 0@# 2(  A$! Q$!_\0
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MUX\26.6))/4FNF\"2W:>(%2W!,3*?-';%=N-HJI2N]T>;EN(=*NDMI:'K1.
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FKK570JDAV0@]=HX_I16\B+&@1%"J!@ =J*X9RYG<]2G#DC8__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>5
<FILENAME>plx-20210428.xsd
<DESCRIPTION>EX-101.SCH
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  9.6.7713.40453 -->
<!--Based on XBRL 2.1-->
<!--Created on: 4/28/2021 10:04:24 AM-->
<!--Modified on: 4/28/2021 10:04:24 AM-->
<xsd:schema targetNamespace="http://protalix.com/20210428" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2019-01-31" xmlns:srt-types="http://fasb.org/srt-types/2019-01-31" xmlns:us-roles="http://fasb.org/us-roles/2019-01-31" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:currency="http://xbrl.sec.gov/currency/2017-01-31" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:naics="http://xbrl.sec.gov/naics/2017-01-31" xmlns:srt-roles="http://fasb.org/srt-roles/2019-01-31" xmlns:country="http://xbrl.sec.gov/country/2017-01-31" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:srt="http://fasb.org/srt/2019-01-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:exch="http://xbrl.sec.gov/exch/2019-01-31" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:us-types="http://fasb.org/us-types/2019-01-31" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31" xmlns:attributeFormDefault="unqualified" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:plx="http://protalix.com/20210428">
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://protalix.com/role/DocumentDocumentAndEntityInformation" id="DocumentDocumentAndEntityInformation">
        <link:definition>00090 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:type="simple" xlink:href="plx-20210428_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="plx-20210428_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/dei/2019-01-31" schemaLocation="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd" />
  <xsd:element name="DocumentAndEntityInformationAbstract" id="plx_DocumentAndEntityInformationAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>6
<FILENAME>plx-20210428_lab.xml
<DESCRIPTION>EX-101.LAB
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  9.6.7713.40453 -->
<!--Based on XBRL 2.1-->
<!--Created on: 4/28/2021 10:04:24 AM-->
<!--Modified on: 4/28/2021 10:04:24 AM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink">
  <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:href="plx-20210428.xsd#plx_DocumentAndEntityInformationAbstract" xlink:label="plx_DocumentAndEntityInformationAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_DocumentAndEntityInformationAbstract" xlink:to="plx_DocumentAndEntityInformationAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_DocumentAndEntityInformationAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document and Entity Information [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Type</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Period End Date</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity File Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Registrant Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Incorporation, State or Country Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Tax Identification Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Address Line One</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Adress Line Two</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, State or Province</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, City or Town</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Postal Zip Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">City Area Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Local Phone Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Written Communications</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Soliciting Material</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Pre-commencement Tender Offer</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Pre-commencement Issuer Tender Offer</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Title of 12(b) Security</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Trading Symbol</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Security Exchange Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Emerging Growth Company</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Central Index Key</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amendment Flag</label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>7
<FILENAME>plx-20210428_pre.xml
<DESCRIPTION>EX-101.PRE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  9.6.7713.40453 -->
<!--Based on XBRL 2.1-->
<!--Created on: 4/28/2021 10:04:24 AM-->
<!--Modified on: 4/28/2021 10:04:24 AM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink">
  <roleRef xlink:type="simple" xlink:href="plx-20210428.xsd#DocumentDocumentAndEntityInformation" roleURI="http://protalix.com/role/DocumentDocumentAndEntityInformation" xmlns="http://www.xbrl.org/2003/linkbase" />
  <presentationLink xlink:role="http://protalix.com/role/DocumentDocumentAndEntityInformation" xlink:type="extended" xlink:title="00090 - Document - Document and Entity Information" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="plx-20210428.xsd#plx_DocumentAndEntityInformationAbstract" xlink:label="plx_DocumentAndEntityInformationAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType_637552010645689763" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentType_637552010645689763" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate_637552010645689763" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentPeriodEndDate_637552010645689763" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber_637552010645689763" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityFileNumber_637552010645689763" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName_637552010645689763" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityRegistrantName_637552010645689763" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode_637552010645689763" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityIncorporationStateCountryCode_637552010645689763" order="5" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber_637552010645689763" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityTaxIdentificationNumber_637552010645689763" order="6" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1_637552010645689763" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityAddressAddressLine1_637552010645689763" order="7" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2_637552010645689763" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityAddressAddressLine2_637552010645689763" order="8" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince_637552010645689763" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityAddressStateOrProvince_637552010645689763" order="9" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown_637552010645689763" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityAddressCityOrTown_637552010645689763" order="10" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode_637552010645689763" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityAddressPostalZipCode_637552010645689763" order="11" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode_637552010645689763" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_DocumentAndEntityInformationAbstract" xlink:to="dei_CityAreaCode_637552010645689763" order="12" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber_637552010645699760" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_DocumentAndEntityInformationAbstract" xlink:to="dei_LocalPhoneNumber_637552010645699760" order="13" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications_637552010645699760" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_DocumentAndEntityInformationAbstract" xlink:to="dei_WrittenCommunications_637552010645699760" order="14" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial_637552010645699760" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_DocumentAndEntityInformationAbstract" xlink:to="dei_SolicitingMaterial_637552010645699760" order="15" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer_637552010645699760" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_DocumentAndEntityInformationAbstract" xlink:to="dei_PreCommencementTenderOffer_637552010645699760" order="16" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer_637552010645699760" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_DocumentAndEntityInformationAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer_637552010645699760" order="17" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle_637552010645699760" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_DocumentAndEntityInformationAbstract" xlink:to="dei_Security12bTitle_637552010645699760" order="18" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol_637552010645699760" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_DocumentAndEntityInformationAbstract" xlink:to="dei_TradingSymbol_637552010645699760" order="19" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName_637552010645699760" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_DocumentAndEntityInformationAbstract" xlink:to="dei_SecurityExchangeName_637552010645699760" order="20" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany_637552010645699760" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityEmergingGrowthCompany_637552010645699760" order="21" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey_637552010645699760" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityCentralIndexKey_637552010645699760" order="22" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag_637552010645699760" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_DocumentAndEntityInformationAbstract" xlink:to="dei_AmendmentFlag_637552010645699760" order="23" use="optional" />
  </presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>plx-20210428x8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="plx-20210428.xsd" xlink:type="simple"/>
    <context id="Duration_4_28_2021_To_4_28_2021_mMZ_Yz-jLEqRey88TjsIbg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
        </entity>
        <period>
            <startDate>2021-04-28</startDate>
            <endDate>2021-04-28</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey
      contextRef="Duration_4_28_2021_To_4_28_2021_mMZ_Yz-jLEqRey88TjsIbg"
      id="Tc_NEjgYrOXekCRXK79Omb3mQ_2_1">0001006281</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag
      contextRef="Duration_4_28_2021_To_4_28_2021_mMZ_Yz-jLEqRey88TjsIbg"
      id="Tc_uiILK5vIgk-ofKrWo2bExg_3_1">false</dei:AmendmentFlag>
    <dei:DocumentType
      contextRef="Duration_4_28_2021_To_4_28_2021_mMZ_Yz-jLEqRey88TjsIbg"
      id="Narr_PUbWSG3oeEeFcMp7FmPd2w">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="Duration_4_28_2021_To_4_28_2021_mMZ_Yz-jLEqRey88TjsIbg"
      id="Narr_eaYniF-Rxk22yS_YV5CdGA">2021-04-28</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName
      contextRef="Duration_4_28_2021_To_4_28_2021_mMZ_Yz-jLEqRey88TjsIbg"
      id="Narr_djafTGn2yUGPnkdzzIK-kA">Protalix BioTherapeutics,&#160;Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="Duration_4_28_2021_To_4_28_2021_mMZ_Yz-jLEqRey88TjsIbg"
      id="Tc_nJVheu79-UGOwoLOKqNN5A_1_0">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="Duration_4_28_2021_To_4_28_2021_mMZ_Yz-jLEqRey88TjsIbg"
      id="Tc_9mhPitmW-EKbtgzwPvBBUA_1_2">001-33357</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber
      contextRef="Duration_4_28_2021_To_4_28_2021_mMZ_Yz-jLEqRey88TjsIbg"
      id="Tc_nS034P5c90urU08TDBU63Q_1_4">65-0643773</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="Duration_4_28_2021_To_4_28_2021_mMZ_Yz-jLEqRey88TjsIbg"
      id="Tc_t3SGCGIj10S-ACspcGI7Rg_4_0">2 University Plaza</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="Duration_4_28_2021_To_4_28_2021_mMZ_Yz-jLEqRey88TjsIbg"
      id="Tc_yLhS9j6LfUmb5vHwN7-vPg_5_0">Suite 100</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="Duration_4_28_2021_To_4_28_2021_mMZ_Yz-jLEqRey88TjsIbg"
      id="Narr_RRcw4rXCdE6xQcN-hlkvsg">Hackensack</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="Duration_4_28_2021_To_4_28_2021_mMZ_Yz-jLEqRey88TjsIbg"
      id="Narr_WByoiqAwnEaIOYlAGJYafw">NJ</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="Duration_4_28_2021_To_4_28_2021_mMZ_Yz-jLEqRey88TjsIbg"
      id="Tc_sxyB9VDpM0KG5ReXoHKIvw_6_4">07601</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="Duration_4_28_2021_To_4_28_2021_mMZ_Yz-jLEqRey88TjsIbg"
      id="Narr_gC2_YoCguEq67usn4aF9SA">201</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="Duration_4_28_2021_To_4_28_2021_mMZ_Yz-jLEqRey88TjsIbg"
      id="Narr_6HcoqHSqhEi2BvxMzU2XXQ">696-9345</dei:LocalPhoneNumber>
    <dei:WrittenCommunications
      contextRef="Duration_4_28_2021_To_4_28_2021_mMZ_Yz-jLEqRey88TjsIbg"
      id="Narr_IRkktNuU8Eux7H9NET-VhQ">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="Duration_4_28_2021_To_4_28_2021_mMZ_Yz-jLEqRey88TjsIbg"
      id="Narr_puWYY9YjhEWb1KFJoKzFgA">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="Duration_4_28_2021_To_4_28_2021_mMZ_Yz-jLEqRey88TjsIbg"
      id="Narr_Z9DEKQG3wkCiSqYFuso-gw">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="Duration_4_28_2021_To_4_28_2021_mMZ_Yz-jLEqRey88TjsIbg"
      id="Narr_jsVqEkTPZkmq5SdFO5DHkg">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle
      contextRef="Duration_4_28_2021_To_4_28_2021_mMZ_Yz-jLEqRey88TjsIbg"
      id="Tc_LPsbvGXSLEGpTDwM8uyYOA_2_0">Common stock, $0.001 par value</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="Duration_4_28_2021_To_4_28_2021_mMZ_Yz-jLEqRey88TjsIbg"
      id="Tc_DHROVgBOTUSFKg2_9Vkmhw_2_1">PLX</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="Duration_4_28_2021_To_4_28_2021_mMZ_Yz-jLEqRey88TjsIbg"
      id="Tc_kzu8ATU73kytCHiHZsXtBA_2_2">NYSEAMER</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany
      contextRef="Duration_4_28_2021_To_4_28_2021_mMZ_Yz-jLEqRey88TjsIbg"
      id="Narr_I6bNWiXTeUebQXavJonwMA">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm139791767453800">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Apr. 28, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_plx_DocumentAndEntityInformationAbstract', window );"><strong>Document and Entity Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Apr. 28,  2021<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-33357<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Protalix BioTherapeutics,&#160;Inc.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">65-0643773<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">2 University Plaza<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Adress Line Two</a></td>
<td class="text">Suite 100<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NJ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Hackensack<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">07601<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">201<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">696-9345<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common stock, $0.001 par value<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">PLX<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSEAMER<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001006281<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_DocumentAndEntityInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_DocumentAndEntityInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>10
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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M;%!+ 0(4 Q0    ( )(PG%)U #U?[P   "L"   1              "  :\
M  !D;V-0<F]P<R]C;W)E+GAM;%!+ 0(4 Q0    ( )(PG%*97)PC$ 8  )PG
M   3              "  <T!  !X;"]T:&5M92]T:&5M93$N>&UL4$L! A0#
M%     @ DC"<4DLO:[]6!   "Q$  !@              ("!#@@  'AL+W=O
M<FMS:&5E=',O<VAE970Q+GAM;%!+ 0(4 Q0    ( )(PG%*?H!OPL0(  .(,
M   -              "  9H,  !X;"]S='EL97,N>&UL4$L! A0#%     @
MDC"<4I>*NQS     $P(   L              ( !=@\  %]R96QS+RYR96QS
M4$L! A0#%     @ DC"<4APX9>H_ 0  / (   \              ( !7Q
M 'AL+W=O<FMB;V]K+GAM;%!+ 0(4 Q0    ( )(PG%(D'INBK0   /@!   :
M              "  <L1  !X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L<U!+
M 0(4 Q0    ( )(PG%)ED'F2&0$  ,\#   3              "  ; 2  !;
H0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@     )  D /@(  /H3      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.21.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>95</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="plx-20210428x8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00090 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://protalix.com/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="plx-20210428x8k.htm">plx-20210428x8k.htm</File>
    <File>plx-20210428.xsd</File>
    <File>plx-20210428_lab.xml</File>
    <File>plx-20210428_pre.xml</File>
    <File>plx-20210428xex99d1.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2019-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>15
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "plx-20210428x8k.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "contextCount": 1,
   "dts": {
    "inline": {
     "local": [
      "plx-20210428x8k.htm"
     ]
    },
    "labelLink": {
     "local": [
      "plx-20210428_lab.xml"
     ],
     "remote": [
      "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "plx-20210428_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "plx-20210428.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd"
     ]
    }
   },
   "elementCount": 24,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2019-01-31": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 95,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "plx",
   "nsuri": "http://protalix.com/20210428",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20210428x8k.htm",
      "contextRef": "Duration_4_28_2021_To_4_28_2021_mMZ_Yz-jLEqRey88TjsIbg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "00090 - Document - Document and Entity Information",
     "role": "http://protalix.com/role/DocumentDocumentAndEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "plx-20210428x8k.htm",
      "contextRef": "Duration_4_28_2021_To_4_28_2021_mMZ_Yz-jLEqRey88TjsIbg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Adress Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "plx_DocumentAndEntityInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document and Entity Information [Abstract]"
       }
      }
     },
     "localname": "DocumentAndEntityInformationAbstract",
     "nsuri": "http://protalix.com/20210428",
     "xbrltype": "stringItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>16
<FILENAME>0001558370-21-004976-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001558370-21-004976-xbrl.zip
M4$L#!!0    ( )(PG%(3%BG4L@,  ,4,   0    <&QX+3(P,C$P-#(X+GAS
M9+57VV[C-A!]+]!_8/4N4;*=36S$623=M@B0M$": GE;T!1M$Y5(E:1BY^]W
M2)&*+Y3C+=HGRYPS,V>NHJX_;^L*O3*EN13SI,CR!#%!9<G%:IZT.B6:<IY\
MOOGQA^N?TO3E[ND!E9*V-1,&4<6(827:<+-&S[)IB$"/3"E>5>A.\7+%$)IF
MG[++RV*<3?+)Q1BEJ;=T1S1H2H&<R5%6])*?O54I9FB"1U=XE(\*5.2S?#(;
M3=#M8X]\!)I+_C%TJ\N9IFM6$V2(6C'S.ZF9;@AE\V1M3#/#N%'2D(IO,RIK
M9R6?C*X21(Q1?-$:]JM4]1>V)&UE("WBGQ; UC5DJV(V&7N '3&D5^@9,.A=
M;3:;;#/.I%J!H[S +X\/?SIR <S%*].FQV\7JLHTH]E*ON).!HK%.,V+=%P$
MI9+QN 8(+'RZ#X?*K@AI>I4ET0M'R0LB*EJ9U+PU3!\K]:*X)R6KF%:01)04
M6^[ERT7D,_8)@[1/+ C*@UQYW 7NA $JI!!M'3=;&H5M !A *:"8XC3HT58I
M&(FW>'J#U 9QN1_$MAJ,88Q?'KCXNZ=&.-5Q^TX4,6Y3/I#77A1)+)6M,&HH
MEDX8\=8:-1C+%(-TAU:44(1*!0DXD2 K7L"2"'"VI>LX;2N)V#^CV/N%WAXQ
M\F-:3*=3[*1]F)S&N8# 4BF.9F!@<H(DQI^M[!X\D7=;9.QA/3/3J %J(+%N
MKO;=G+'BP@[C'^^PE MMB*!L=T#YB3(?XIMJ^\%2AHV.D-OI1 @ &'ASN;-P
MVC1<+*4_@D-;N)G-U3-D&MF'OY[NXTY<1K_X]UOXO17E+\)P\W8/9E7M'":(
M0V7.0O9$ I62+;G@CG8.9<Q1BH*!W4<B2M190SOFKO&AC4/S+;Q8_Q W[KE1
M3(,MIVD7CM?VD%.:E%2TK?Z%XCNS83U_&FIR4*HP^4]LB=S4S>R(S!/-ZZ:R
MC>+.UNX= >V2AL[X"M%FT$4!8<V?Z#Q7Z\,$>;_!!%'TR,K14K MU#!E.(SQ
M^];"_U54%5E\;U2@PJK_)YQK?#AC_F1_%MTD0F12&22.;ENGUD!W47N0U!D[
MH6+_]>LFM4=I,8+%EH'KP/<TC?AMX4P"0<%ZOOA.GT-WLYAK/:1D'])W[2,*
M_F+J.+ROJMB*NEUHHP@UW5*#YOMZ'KIK8+?AX;VCX)/AWK#:3C2$T@*,F]9J
M_*9DVP0@!PA<K+V1>6)4"W !WPQD85NS^]]AH0VY+)^=F[)5?O/:&+NFZ_)U
M\PU02P,$%     @ DC"<4ADIA*ZH!0  <3\  !0   !P;'@M,C R,3 T,CA?
M;&%B+GAM;-6;[V_B-AS&WT_:__ =]V:3+H2DW.Z*VIYHKS=5H]?J8-IITW0*
MB0%KP4:.*?#?S\X/(,$.O[I@WK1I_/CQ]S&?)$Y(KS[.QR&\(!9A2JYK3KU1
M T1\&F RO*Y-(\N+?(QK'V]^_.'J)\OZ=ONU P'UIV-$./@,>1P%,,-\!#TZ
MF7@$'A%C. SAEN%@B  NZ[_6W[]W+NK-1O/=!5A6ZG3K1:(G)1!;NG5GV7*7
MNE+2@J;M?K#=ANN TV@UFBVW">W'I?)1E#G VZ4A)O^VY(^^&!1$8!*UYA&^
MKHTXG[1L>S:;U6<7=<J&PJ#AV-\>.UU_A,:>A4G$/>*C&@A]*XIW=JCO\7BV
MUKK/^RS,#"[LY5A:A?S+RF26W&4YKG7AU.=14$M+E,T[#)+)96O EQW6Q>_L
MI'$IW;!.XSN7EY=VW%H3$P>03IW71V%';$'<U.*+";JNH3E')$"RW'@OHR$J
M*5<VVRMGZ4W]G&$H)Y:RS&_$T."Z-@GGEOQ4&TWW@YR<-V+']T\I@6T2W!..
M^>*!#"@;QQ]+NQ]QYOD\LXF+CWUV[2:G:*=YMY=)Y!AMEH_C,3^K06QNF9U4
M8?M4T#;A5NR8=1\P.MXK05(%W;W/][ ?'IX\%YNAB$Y9?,CLCL5ZVCT_L&7I
MHJ,\9R%B_='=(\M--@AX)(!D&%@;!_[.1OKG*BET+WYE 5%V.$;(KP_IBQT@
M+*IP+N6&)3>LAI,>_&_$KF7NGO M3(NBV5!>=4$DE\4V _G3EG@T9]*M<I2>
M$<-4'$7!)W%Q+8E:U)T!7,IH1<IR(L-Q4]=Z-'>)K3C%!2"-*T,P.:=^QB'Z
M,AWW$5,D5T@,!D\7*&.NV&XH;MHR#R4MO7A*1T@L*V;L*QIB>:TF_(LW5IWE
M-#+C65,'R_.6UQC-G*;4([E;N8*TK9B]!W'7S":4Q8O&+A<GV#LZ)9PM[FB@
M1W%;+^/)W"EV'M32+D9SNUOE1V*<&^0MQ,, 99 .!7*LBMGN>?.'0"PA\  G
MSSZV7,CU>N-YWA(U3[)&;#3#VVH^DEYA#WG_TRP%VD$@YBY*?W4P08YV2M1:
MXU$MB9C'5"$T&M&R>H_$,_5\FVV =(<G4O49=3.BN\=TN.>)I[LKGNZ9X>G^
M#WBNZ.S-Z&GHC)<>3^R9T1=,?/TB5BL_%T8U0968%K3G0*JNY->"=;E$S48X
M#:YW8O.)]>B,;)N0G/)<(-V,I^1S)3L'-!75OA:5TEI"*<U/ ^0SC;@7_H4G
MI8\ -.)SP5(94DEF3GD.<*H+?BT^$W<0]M7>TLOCHLV0IX&RT&PPAJH@&7CK
M;8:BIBSQ4+CBDYUTJY8E^2Y,^#RB1/_5CD)B,%.Z0!E7Q79#V=*6>2A?L2'$
MCE4_S_F38<X1N:/C\92DSY0B16:=SF#:2J-ER"E%AG)77NNA\*6ND+>M#, N
M#;&/.2;#1W&?P["G2JX4&8R>/E3&W:;"4.A*"CV4N)4E9)Z5X?;,D 0=B8\O
M?O=(OF3)G@8#Y=6U5&PP?MM#9ACJE8;BN$/!AV(IK"U_S1L2<XC=3P7H0Q1-
M$=L+4U67\X%5&UB#[(;^/,#5E_UJ^"9#G(;B+O*G8EVQ<-Q^#_-0=2NLD!A,
MJ2[0\GI>:#>40FV9AU(7NP =@./^W/\%,O_*0.LQ3_XW37<Q[E-5X&*[P8@I
MHV1\Y1H-A4M=X\%D)6Z0V%5^YKJ?^R-1.-*\ZZB1&8Q76;#B66Q=8RALI:4>
M?&>2FD+F>HIW'>_'B T%^;\Q.N,CL6B8>&2A?9JN4QM,X@XQ\U]Q**6&<KE+
MQ4=^R9&90^(.J7W%F-Z)-2;SP@>QNIS_CO2 ;NJ,1U,3+0]E060TCKI:CP0Q
MM878%X1Q90BVQ1U.(.]R/H?>4!&[V&XP<LHH&6JY1D,14]=X*%I+-Y!VZT!=
MV:N1.V)+_O-YNBOM??,?4$L#!!0    ( )(PG%*3W&FJE00  -(J   4
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M1L/(JU0\V,=O[*FW.^WMM.'MBV\?_P%02P,$%     @ DC"<4B.Y=9->%
M3Y$  !,   !P;'@M,C R,3 T,CAX.&LN:'1M[5WM<]J\LO]^9N[_H)OGGM-D
MIC;&-J])<X80DM DA )IDGYA9%N B[$<V;SUK[\KV2:&D)"V(>^=YR%@R_)J
M=_73[FHE[?QW,G#0B##?INZ73VE9^82(:U++=KM?/IVW#J3\I__N_@O!/_&!
MT,[_2A*R+_<:)\BBYG! W "9C." 6&AL![TB:E'/PRXZ)8S9CH/VF&UU2?1(
M0<[*N5Q:DW5%SVA(DG:3U>YA'VJA;C$JG9;3BT7*T:MX(3VEYE.JHJ916BDJ
M>A&^E$X7'PAK.K$-AMDT;FD1JE9FA&1OO25\J$G8R#8)^DH-5-TO(LTDN$!T
M3<JI>E;2.UB1L-G!4B';4> _K*MF-E$3_-GI!<!>8+'K%RUB?]GH!8%73*4F
M!G-DGYAREXY2< -:D2Y(2EK2TAMA\5G1\7@LCS69LFXJ72@44A->952HZ#F3
M64&/T0 []D0VZ4!P1='5?%S0L=W^7)6" EZIJBA:BM\V@/EQ\<FM\G,D\+NS
MHE"1%<RW+*HWDPIOSHHN;1443*<N3T^:9H\,L&2[?H!=<T:*/0DDX-3<DS'G
M;!<H(5Q6J8!AU^]0-L !R)?S,R,I^1M^\GJ6,V!5):JD9F\JN8N):2U145R<
MD<Z=3,^FX&Z2B?8]\IDQ97>G1["UNS,@ 4:\N$2NA_;HRX9)W0"ZHA1,/6!=
M].O+1D F02K4F-3N3F '#MG=2<5_P[H,:DUW=RQ[A/Q@ZI O&P/,NK8K!=0K
M:HH7;,-;4W![KHQE^YZ#IT67NH07L"=%7AMAX5?;LH@KOD*!&J $L\V0JDG0
MX%S9'S+!Y+;>5O-MKJ[M%DW\&)S^:%_]DGZ>5*X;9)K/MW[Z5:.[@5P\X&\G
M=K'B0C.F96@FPT[5M<CDF$PWD&U]V6B9[5KE9_>*G5V2?KEQ>9PKG T,;?"M
MK;;3&[L*:!P(0,VG=U)S%*Z7X!)@I<7Q\L#!W1FA0[MZ<IP95;M]B7:.V055
MC<JDV]8XH1WL^.06C:EY!H,:$0:83?S='=XQB[[H2$ T$AVUV!-J"% AQ:@@
M3WQK([K+%>;+AF\//(>K5VJ^BO!MR5>(GSX=,O%+*&XQXI-HTA_R*:Z*"*G&
MOVR+_^[8A"%!$ED* ^7J\;Q0%Q_>C2_-U^X!/ZD5_X(>QH)]&%QV.9V2HDMJ
M/G[NYMZ,3.N.HO&=^'?\DM0<JV*^SAB92G2@6YUM@"?2V+9@<(4F_GO;PQ8?
MGR6'= *X(FN9FVO,[O9N+E+?YK* %SD@E)'HJ8EZ38=@5C1HT-M>?,6M)P>
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M8^M#Y@^Q&Z" @I]O<K:'72&M(<I0.K-I;847:.>IT3;[,+0->H23/F2@-$!
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M/VU2M# (S%:<OJBYB!#@ >E$C9$)+ZIRL@<91,#K*%\DO2#T55ABURMY-W@
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M*.K#V'= D;'9]!?4.04O'C.R][5%$SMW9WMY]*JDO,[VW4:+/PF$WF&@\K#
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M4(<"'D<*A!VC\C($I81=0D44/ )+$/0"?M]5\'>M8>B%::!#YND0.I8M9?H
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M              "  ;H)  !P;'@M,C R,3 T,CA?<')E+GAM;%!+ 0(4 Q0
M   ( )(PG%(CN7637A0  $^1   3              "  8$.  !P;'@M,C R
M,3 T,CAX.&LN:'1M4$L! A0#%     @ DC"<4GPP'PH=&0  M&   !<
M         ( !$",  '!L>"TR,#(Q,#0R.'AE>#DY9#$N:'1M4$L%!@     %
-  4 2 $  &(\      $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
